New shot aims to tame rheumatoid arthritis flares
NCT ID NCT06590090
Summary
This study is testing whether a new injectable drug called Natrunix, when added to standard methotrexate treatment, can better control the symptoms of moderate-to-severe rheumatoid arthritis. About 108 adults who still have significant joint pain and swelling despite taking methotrexate will receive either Natrunix or a placebo injection for 14 weeks, followed by an option for everyone to try Natrunix. The main goal is to see if the combination reduces joint tenderness and swelling more effectively.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.